Heart failureUsefulness of Intermediate Amino-Terminal Pro-Brain Natriuretic Peptide Concentrations for Diagnosis and Prognosis of Acute Heart Failure
References (9)
- et al.
Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath
J Am Coll Cardiol
(2003) - et al.
The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study
Am J Cardiol
(2005) - et al.
Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failurean analysis from the Breathing Not Properly multinational study
Ann Emerg Med
(2005) - et al.
NT-proBNP testing for diagnosis and short-term prognosis in acute congestive heart failurean international pooled analysis of 1256 patients
Eur Heart J
(2006)
Cited by (89)
A novel electrochemiluminescent immunosensor for the detection of NT-proBNP based on a Au/ZIF-67 nanocomposite
2022, Journal of Electroanalytical ChemistryQuantum dot enabled lateral flow immunoassay for detection of cardiac biomarker NT-proBNP
2018, Sensing and Bio-Sensing ResearchCitation Excerpt :Furthermore, increased levels of NT-proBNP correlate with reduced left ventricular ejection fraction and abnormal ventricular systolic function [5,6]. While circulating levels of BNP have been used to monitor cardiac function [7–9], its bio-inert product, NT-proBNP, has a longer biological half-life and can be used to more accurately separate patients with normal and impaired systolic function, as compared to BNP measurements alone [9–13]. A study investigating methods for the quantification of BNP and NT-proBNP revealed much greater variability (coefficient of variation of >30) for detection of BNP, as compared to NT-proBNP [7].
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017, Journal of the American College of CardiologyCitation Excerpt :In 2 studies with ARNI, NT-proBNP levels were reduced (12,14), with the reduction in 1 study being associated with improved clinical outcomes (12). A substantial evidence base exists that supports the use of natriuretic peptide biomarkers to assist in the diagnosis or exclusion of HF as a cause of symptoms (e.g., dyspnea, weight gain) in the setting of chronic ambulatory HF (15–21) or in the setting of acute care with decompensated HF (22–30), especially when the cause of dyspnea is unclear. The role of natriuretic peptide biomarkers in population screening to detect incident HF is emerging (31–37).
The International Collaborative of NT-proBNP Study was partially sponsored by unrestricted grants from Roche Diagnostics, Basel, Switzerland.